Pharmaceuticals, Biotechnology & Life Sciences

AbbVie keeps dividends rising while fueling drug‑pipeline growth, balancing strong cash flow, R&D investment, and value‑based reimbursement to boost shareholder returns and patient access.

Discover how Bayer’s new tyrosine‑kinase drug HYRNUO and its winterrapé bio‑fuel partnership accelerate cancer care and low‑carbon energy—boosting health, sustainability, and shareholder value.

Merck KGaA’s EMD Serono expands with oral fertility agonists and high‑potential ADCs, boosting pipeline value and market‑access strategy.

Novo Nordisk’s latest share‑repurchase and halted cardiovascular trials reveal a complex mix of investor confidence, regulatory scrutiny, and a strong weight‑loss portfolio – insights investors can’t miss.

Johnson & Johnson unveils 24 new mental‑health abstracts, spotlighting GABA‑B modulators, IL‑6R antibodies, gene‑editing and digital tools to fast‑track breakthroughs and diversify its pipeline.

Genmab’s modest share‑capital lift and unchanged board fees focus on RSU‑based incentives and heightened transparency, driving a 2,900 DKK target‑price upgrade.

Eurofins Scientific shares rise modestly in a weak French market, showing resilience as it boosts R&D and AI‑powered bio‑analysis services for value‑based contracts and patient‑access growth.

Novartis’ late‑stage drug failure rattles the Swiss Market Index; read how the setback impacts R&D, regulation and upcoming index reshuffle for savvy investors.

Thermo Fisher’s new Bengaluru semiconductor lab shows how life‑science analytics can cross into high‑tech, boosting pharma, biotech and M&A prospects while navigating patent cliffs.

Swiss healthcare market faces value‑based pricing and operational efficiency challenges—discover how Novartis, Lonza and providers can thrive by balancing cost, quality and reimbursement.